Total Funding
48
45
Total FundingSeries C raised
Growth Score
-4 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
81169
Gliknik develops therapies for patients with cancer and immune disorders.
Henrik S.Olsen: Director, Drug Discovery
David S. Block: Founder, President and CEOPast Role: Celera, Chief Operating Officer
About the Company
Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous
immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.
